FIL-1 theta DNAs and polypeptides
OwnerJohn E. Simsinventor
Life of this patent
Estimating the term…
Abstract
The invention is directed to novel, purified and isolated FIL-1 theta polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.
Claims15
A method for identifying compounds that alter FIL-1 theta activity, the method comprising:
- (a) mixing a test compound with the polypeptide selected from the group consisting of:
- (i) a polypeptide comprising the amino acid sequence of SEQ ID NO:4, except that the amino acid at 44 is selected from the group consisting of threonine and isoleucine and the amino acid at 51 is selected from the group consisting of aspartic acid and alanine;. and,
- (ii) a polypeptide that is a fragment of the polypeptide of SEQ ID NO:4, wherein the fragment exhibits FIL-1 theta activity, and
- (b) determining whether the test compound alters FIL-1 theta activity of the polypeptide.
A method for identifying compounds that inhibit the binding activity of FIL-1 theta polypeptides, the method comprising:
- (a) mixing a test compound with a polypeptide selected from the group consisting of:
- (i) a polypeptide comprising the amino acid sequence of SEQ ID NO:4, except that the amino acid at 44 is selected from the group consisting of threonine and isoleucine and the amino acid at 51 is selected from the group consisting of aspartic acid and alanine;. and,
- (ii) a polypeptide that is a fragment of the polypeptide of SEQ ID NO:4, wherein the fragment binds an IL-1 receptor family member and a binding partner of the polypeptide;
- and
- (b) determining whether the test compound inhibits the binding activity of said polypeptide.
A combination method for screening a plurality of molecules to determine whether the molecules affect a biological activity of FIL-1 theta, the method comprising:
- (a) selecting a molecule that affects an ability of FIL-1 theta to bind an IL-1 receptor family member;
- (b) contacting the selected molecule and a FIL-1 theta polypeptide with cells capable of exhibiting a biological activity when contacted with FIL-1 theta polypeptide selected from the group consisting of a polypeptide comprising the amino acid sequence of SEQ ID NO:4, except that the amino acid at 44 is selected from the group consisting of threonine and isoleucine and the amino acid at 51 is selected from the group consisting of aspartic acid and alanine and a polypeptide that is a fragment of the polypeptide of SEQ ID NO:4 that binds an IL-1 receptor family member, and
- (c) analyzing the cells for the occurrence of the biological activity, wherein if the biological activity observed in the presence of the selected test compound differs from the biological activity that is observed when the selected test compound is absent, the selected test compound affects the biological activity of FIL-1 theta,
Dependencies are inferred from the claim text.